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Tasser online server and, the structure were analyzed with UCSF
Chimera package. The phylogenetic analyses showed that the
Asian EIV population has a geographic division. All Japanese strain
grouped in Florida Clade 1 next to USA strains. The EIV population
frommainland (China, Mongolia, Kazakhstan and India) belong to
Florida Clade 2. Furthermore, a geographic association is
observed. Two EIV population can be shown Indian strains cor-
responding to 2008 and 2011 EI outbreak. In China, the 2007-
2008 strains from a monophyletic cluster. Interesting, the strain
Mongolia/56/2011 evolve to the Mongolia 2011 outbreak and,
similar strain were detected in 2012 in Kazakhstan (South
Kazakhstan/236/2012). The strains detected in China in 2013
(Heinlongjian/SS1/2013 and Xuzhou/01/2013) were linked with
the strains detected in Mongolia in 2012. Mapping the amino acid
(aa) substitution, four differences (V78A, S159N, S162P and
K189Q) are found in Huabei/1/2007 respect to the vaccine strain
Ibaraki/1/2007, three in the antigenic site B (top of the protein)
and one in E. Comparing the vaccine strain against Heinlongjian/
SS1/2013, two extra aa substitution can be seen (A144T and
E198G). Our study support the understanding of the molecular
evolution of H3N8 EIV in Asia and will facilitate future in-
vestigations of the epidemiology of these viruses because, the EIV
strains still evolving in the population. Furthermore, contributes
to the monitoring of vaccines the currently available.
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Pseudotyped viruses (PVs) provide a ﬂexible, safe platform for
fundamental virological studies and antibody/antiviral screening
assays. Generation of inﬂuenza PVs involves co-transfection of
producer cells with plasmids encoding the necessary viral com-
ponents. The pseudotype virus neutralization assay (PVNA) is a
sensitive technique to measure protective antibody responses.
Furthermore, many traditional methodologies (e.g. HI, SRH) detect
only surface glycoprotein binding antibodies whereas the PVNA
quantiﬁes infectivity-neutralizing responses. Two enzymes crucial
for the infectivity of inﬂuenza viruses are; HA-cleaving cellular
proteases and neuraminidase (NA). Transmembrane protease
serine 2 (TMPRSS2) has been shown to cleave group 2 inﬂuenza
HAs in both a native and PV context, including an equine H3 PV.
However the efﬁcacy of alternatives, such as TMPRSS4 and human
airway trypsin-like protease (HAT), has not been tested. In nature,
inﬂuenza NA cleaves sialic acid permitting viral egress. When
generating PVs, an exogenous source of NA (often from Clostridium
perfringens) is typically added for cleavage. However, an endoge-
nous source of NA (i.e. NA encoding plasmid) has rarely been used
in the transfection mix to produce inﬂuenza PVs and not yet tri-
alled for H3. Producing high titre PVs is important as this permits
minimal quantities to be used in PVNAs, and repeat experiments
can be carried out using the same batch of virus, minimising intra-
study variability. Here we investigated the role of different pro-
teases and NAs to optimise the generation of PVs. Initially, inﬂu-
enza PVs were generated via co-transfection of HEK293T/17 cells
with plasmids expressing the A/equine/Richmond/1/2007 inﬂu-
enza H3 HA, HIV gag-pol, ﬁreﬂy luciferase reporter and testendoprotease (with the standard addition of exogenous NA). The
nature and quantity of protease plasmid affected PV titre and so the
optimum was subsequently used in a ﬁve plasmid co-transfection
incorporating a different NA plasmid representative of N1-4, 8 and
9 subtypes. Some, but not all, NA subtype plasmids enabled gen-
eration of PVs with H3 HA and there were notable differences in
production titre. PVs were then taken forward into PVNAs, to
determine whether the presence of NA in the PV envelope in-
ﬂuences antibody neutralization. Results showed that neutraliza-
tion was not impeded by the presence of NA.
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Equine inﬂuenza (EI) is a major respiratory disease of the horse
caused by the highly infectious equine inﬂuenza virus (EIV), out-
breaks of which induce signiﬁcant welfare and economic conse-
quences. EI vaccination is one of the most effective methods of
prevention, with diverse EI vaccines commercially available
worldwide. As for all inﬂuenza viruses, EIV constantly evolves
through antigenic drift in order to evade natural and vaccine im-
munity. Genetic and antigenic variations are monitored by the OIE
(World Organisation for Animal Health) Expert Surveillance Panel
for EI vaccine composition (OIE ESP) in order tomaintain optimal EI
vaccine protection. In 2010, the OIE ESP recommended that EI vac-
cines should contain EIV strains fromboth Florida Clade 1 andClade
2 sublineages (FC1 and FC2, respectively). In this context, up-to date
reference antiserum standards are essential for normalisation of
immunogenicity assays, such as the single radial haemolysis assay
(SRH) and the haemagglutination inhibition (HI) test, for EI vaccines
batch potency assay and efﬁcacy evaluation in clinical trials, and for
diagnostic tests. A biological reference preparation (BRP) equine
antiserum to the FC1 EIV strain A/eq/South Africa/4/03 is currently
available, but none exist for FC2EIV strains. This FC2 BRP is urgently
required. Study aims: to produce and establish a new candidate
equine antiserum speciﬁc to the EIV strain A/eq/Richmond/1/07
(FC2 representative strain) asan European Pharmacopoeia (Ph. Eur.)
BRP and as an OIE-approved International Standard. Objectives &
Results: 1) BRP production: two Welsh mountain ponies, seroneg-
ative for EIV, were successfully immunised against the EIV strain A/
eq/Richmond/1/07byexperimental infection.A total of1.230 litre of
serum was collected from day 14 to day 23 post infection and
titratedby SRHusing the EIV strainA/eq/Richmond/1/07 as antigen.
SRH antibody titres ranged from 144mm2 to 217mm2. 2) BRP
titration and validation: after pooling and inactivation with Beta-
propiolactone, a batch of BRP and SRH/HI antigens will be provided
to up to 10 independent collaborative laboratories for SRH and HI
titration. Individual titrations will be analysed by the EDQM statis-
tics department in order to deﬁne the new FC2 BRP potency titre.
Conclusion: the availability of up-to date reference standards is
essential todevelop, evaluateandstandardise thedifferentmethods
of prevention against EI (e.g. EI vaccines and serological diagnostic
tools). This presentation aims to review the multi-stage process of
production and establishment of a new horse antiserum BRP spe-
ciﬁc to the FC2 representative EIV strain, with results currently
obtained highlighted and pivotal stages presented and discussed.
